Strategic partnerships Zealand Pharma maintains strong collaboration with major pharma players for obesity programs, including Roche and Boehringer Ingelheim, signaling a buyer readiness pattern for co-development and licensing discussions with large partners.

Clinical pipeline strength With ten drug candidates in clinical development and two marketed, there is a robust pipeline focused on obesity, chronic inflammation, and rare diseases, presenting multiple entry points for advisory, co-development, or equity investment conversations.

US market footprint Presence in Copenhagen and a team in the US, plus a dedicated US marketing leadership appointment, indicates growing US commercial ambitions and opportunities for local sponsorships, distribution deals, or regional clinical trial partnerships.

Digital and tech readiness Adoption of a modern technology stack (GitHub, Terraform, SAP, iCIMS) and standard enterprise tools suggests potential for partnerships around data analytics, cloud-based trial management, or digital health collaborations to accelerate development and scale operations.

Financial and investor signals Triple-digit funding level and a substantial revenue range, along with recent conference activities and advisory engagements, create openings for strategic investments, collaboration agreements, or milestone-driven financing discussions with potential acquirers or lenders.